Holen Sie sich die Stockscreener-App
168.84
2.98%
4.89
Handel nachbörslich:
168.82
-0.02
-0.01%
Schlusskurs vom Vortag:
$163.95
Offen:
$166.77
24-Stunden-Volumen:
3.83M
Relative Volume:
1.29
Marktkapitalisierung:
$261.85B
Einnahmen:
$60.48B
Nettoeinkommen (Verlust:
$10.40B
KGV:
50.71
EPS:
3.3297
Netto-Cashflow:
$8.05B
1W Leistung:
+8.36%
1M Leistung:
+1.66%
6M Leistung:
-15.87%
1J Leistung:
+0.66%
1-Tages-Spanne:
$166.66
$169.24
1-Wochen-Bereich:
$158.31
$169.81
52-Wochen-Spanne:
$153.41
$212.71
Astrazeneca Plc Stock (AZN) Company Profile
Compare AZN vs LLY, JNJ, ABBV, MRK, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AZN
Astrazeneca Plc
|
168.84 | 261.85B | 60.48B | 10.40B | 8.05B | 3.3297 |
LLY
Lilly Eli Co
|
1,286.79 | 1.15T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
259.42 | 625.18B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
289.08 | 510.84B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
148.30 | 365.88B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
153.63 | 292.01B | 54.66B | 13.58B | 16.05B | 7.0171 |
Astrazeneca Plc Stock (AZN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-09-15 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2026-09-09 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2026-07-13 | Herabstufung | HSBC Securities | Buy → Hold |
| 2026-01-27 | Eingeleitet | Citigroup | Buy |
| 2025-10-27 | Fortgesetzt | Jefferies | Buy |
| 2025-10-16 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2025-04-15 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2025-02-13 | Hochstufung | UBS | Neutral → Buy |
| 2025-02-12 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-11-20 | Hochstufung | UBS | Sell → Neutral |
| 2024-11-06 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-09-13 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-04-16 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-02-08 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2024-01-23 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-01-16 | Fortgesetzt | UBS | Sell |
| 2024-01-03 | Herabstufung | Jefferies | Buy → Hold |
| 2023-12-18 | Eingeleitet | HSBC Securities | Buy |
| 2023-09-25 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-07-12 | Hochstufung | UBS | Neutral → Buy |
| 2023-07-05 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2023-04-11 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-01-05 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-09-15 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-09-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-29 | Hochstufung | Argus | Hold → Buy |
| 2022-06-14 | Herabstufung | UBS | Buy → Neutral |
| 2022-02-11 | Hochstufung | DZ Bank | Sell → Hold |
| 2021-12-07 | Herabstufung | Jefferies | Buy → Hold |
| 2021-08-12 | Fortgesetzt | JP Morgan | Overweight |
| 2021-04-12 | Herabstufung | Argus | Buy → Hold |
| 2021-03-16 | Hochstufung | Jefferies | Hold → Buy |
| 2021-02-25 | Hochstufung | UBS | Neutral → Buy |
| 2021-01-15 | Eingeleitet | Deutsche Bank | Buy |
| 2020-12-07 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-30 | Hochstufung | UBS | Sell → Neutral |
| 2020-11-11 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2020-09-29 | Eingeleitet | Berenberg | Buy |
| 2019-11-22 | Eingeleitet | SVB Leerink | Outperform |
| 2019-10-25 | Hochstufung | Liberum | Hold → Buy |
| 2019-04-02 | Herabstufung | UBS | Neutral → Sell |
| 2019-02-05 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2019-01-25 | Hochstufung | Shore Capital | Hold → Buy |
| 2018-12-11 | Fortgesetzt | Jefferies | Hold |
| 2018-10-09 | Eingeleitet | Guggenheim | Buy |
| 2018-08-16 | Herabstufung | Jefferies | Buy → Hold |
| 2018-03-19 | Hochstufung | Jefferies | Hold → Buy |
| 2018-02-06 | Bestätigt | Leerink Partners | Mkt Perform |
| 2018-02-05 | Bestätigt | Bernstein | Outperform |
| 2018-01-18 | Bestätigt | Leerink Partners | Mkt Perform |
| 2017-12-29 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2017-10-16 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2017-09-25 | Hochstufung | Exane BNP Paribas | Neutral → Outperform |
| 2017-09-22 | Hochstufung | Bernstein | Mkt Perform → Outperform |
Alle ansehen
Astrazeneca Plc Aktie (AZN) Neueste Nachrichten
The Zacks Analyst Blog Highlights AstraZeneca, Roche, Puma Biotechnology and Olema Oncology - Zacks Investment Research
4 Breast Cancer Stocks to Watch During Breast Cancer Awareness Month - Zacks Investment Research
Astrazeneca (AZN) Rises Higher Than Market: Key Facts - Zacks Investment Research
Can Gilead's Deal With VIR Boost Its Oncology Pipeline and Growth? - Zacks Investment Research
The Zacks Analyst Blog Highlights Mastercard, AstraZeneca and Sandisk - Zacks Investment Research
Top Research Reports for Mastercard, AstraZeneca & Sandisk - Zacks Investment Research
Will Keytruda Continue to Aid Merck's Top Line in Q3 Earnings? - Zacks Investment Research
AstraZeneca reports HICKORY Phase III results for AstraZeneca stock - ad-hoc-news.de
AstraZeneca Summit Deal: What Does Completion Unlock? - Kalkine Media
AstraZeneca PLCAmerican Depositary Shares (NYSE:AZN) Stock Quote - FinancialContent
AstraZeneca HPP Drug Shows Gains Despite Missing Key Phase III Endpoint - Yahoo Finance
AstraZeneca PLC (AZN) Presents at American Society for Bone and Mineral Research (ASBMR) 2026 Annual MeetingSlideshow (NYSE:AZN) 2026-10-12 - Seeking Alpha
AstraZeneca's efzimfotase alfa adult data point to $4.4bn peak sales potential, says Citi - Proactive financial news
AstraZeneca Says Rare Disease Drug Shows Improvements in Inherited Bone Disorder Despite Missing Key Trial Goal - Benzinga
AstraZeneca pins bone disease drug’s Phase III failure on high placebo response - Clinical Trials Arena
Weekly Recap: U.S. $50B expansion and Summit stake funding ivonescimab - TradingView
AstraZeneca PLC (AZN) stock price, news, quote and history - Yahoo Finance Australia
ASTRAZENECA PLC CEDEAR EA RE 0. (AZND.BA) Q1 FY2026 earnings call transcript - Yahoo Finance
Cancer Stocks to Consider as Oncology Innovation Accelerates - Zacks Investment Research
AstraZeneca (AZN) Seeks FDA Approval for New Lung Cancer Treatment. Can It Fuel Oncology Growth? - Yahoo Finance
AstraZeneca falls Thursday, underperforms market - MarketWatch
Pfizer's Oncology Outlook: Key Drivers to Watch Ahead of Q3 Results - Zacks Investment Research
Form 4 ASTRAZENECA PLC For: 8 October By Investing.com - Investing.com UK
How Is Eli Lilly's Oncology Portfolio Poised Ahead of Q3 Earnings? - Zacks Investment Research
Will Linzess Continue to Aid Ironwood's Top-Line Growth in Q3? - Zacks Investment Research
AstraZeneca (LSE:AZN) Opened A $1 Billion R&D Center In Kendall Square - Yahoo Finance
Jefferies maintains 'buy' rating on AstraZeneca ahead of third-quarter results - Proactive financial news
AstraZeneca PLC : Buy rating from Berenberg - www.marketscreener.com
US bank expects AstraZeneca to beat third-quarter forecasts as path clears to key lung cancer data - Proactive Investors
AstraZeneca PLC : Jefferies gives a Buy rating - www.marketscreener.com
AstraZeneca PLC : Bernstein reaffirms its Buy rating - www.marketscreener.com
AstraZeneca Takes Drug-Pricing Law Challenge To 4th Circ. - Law360
Astrazeneca (AZN) Exceeds Market Returns: Some Facts to Consider - Zacks Investment Research
Astrazeneca (AZN) Exceeds Market Returns: Some Facts to Consider - Yahoo Finance
AstraZeneca’s Real World COPD Study in Russia Signals Strategic Respiratory Focus - TipRanks
AstraZeneca advances Tuesday, outperforms market - MarketWatch
Merck Stock Down 7% in a Month: Is the Dip a Buying Opportunity? - Zacks Investment Research
Citi raises AstraZeneca target to £186 as tozorakimab prospects improve - Proactive financial news
AstraZeneca opens new R&D centre in Cambridge, US - Pharmaceutical Technology
AstraZeneca Invests Over $1bn in Massachusetts - marketscreener.com
AstraZeneca Launches Research, Development Center in US - marketscreener.com
‘We’re here at the party now:’ AstraZeneca opens new Kendall hub with big hiring plans - The Business Journals
AstraZeneca CEO Soriot says drugmaker can grow without big acquisition - Seeking Alpha
AstraZeneca CEO says Summit drug could drive next generation of cancer combinations after $2 billion investment - CNBC
AstraZeneca to invest over $1 billion in Massachusetts, boost workforce - marketscreener.com
AstraZeneca to invest over $1B in Massachusetts ops - Breakingthenews.net
A Massachusetts investment will expand AstraZeneca’s state workforce by over 50% in coming years. - Stock Titan
AstraZeneca opens new global strategic R&D center in Kendall Square, Cambridge, Massachusetts - Financial Times
AstraZeneca PLC (ZEG.DE) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Summit Therapeutics Closes $2 Billion AstraZeneca Investment - grafa.com
Finanzdaten der Astrazeneca Plc-Aktie (AZN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Astrazeneca Plc-Aktie (AZN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Sharma Mani | See Remarks |
May 20 '26 |
Sale |
185.78 |
11,893 |
2,209,482 |
19,262 |
3.30%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):